Introduction: Activating mutations in the EGFR gene have been shown to confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced NSCLC. However, wide interpatient variability in treatment outcomes in response to EGFR tyrosine kinase inhibitors in these patients remains unaccounted for. This study aimed to evaluate the influence of EGFR mutation types and subtypes on survival outcomes in advanced Asian patients with NSCLC receiving first-line gefitinib therapy.
Introduction
NSCLC accounts for approximately 75% to 80% of all lung cancer cases, and remains the leading cause of cancer-related death worldwide. 1 As our understanding of the underlying molecular drivers of progression for NSCLC evolved and targetable oncogenes were discovered, rapid progress has been made in overcoming the therapeutic plateau in treatment of NSCLC. In particular, the use of EGFR tyrosine kinase inhibitors (TKIs) in the treatment of patients with advanced NSCLC harboring activating EGFR mutations has markedly improved survival outcomes, particularly in patients of Asian descent, in whom these mutations have been reported to be more prevalent. 2, 3 Unfortunately, wide interpatient variability in treatment outcomes in response to EGFR TKIs continues to be observed and there remains a pressing need to further optimize treatment strategies in these patients.
EGFR mutations have been reported to occur almost exclusively in exons 18 to 21 of the gene, which encode the kinase domain and consist mainly of in-frame deletions and insertions. [4] [5] [6] More than 80% of these mutations occur in codons 746 to 753 in exon 19 and codon 858 in exon 21, leading to missense mutations flanking the adenosine triphosphate-binding pocket, which is critical for EGFR tyrosine kinase activity. [7] [8] [9] This leads to dysregulation of the pathway and causes tumor cells to be highly susceptible to EGFR TKIs, which explains at least partially the clinical effectiveness of EGFR TKIs in patients carrying these mutations. However, there remain several significant knowledge gaps in our current understanding of the influence of this heterogeneous group of mutations on treatment outcomes to EGFR TKIs in patients with NSCLC.
Several studies have documented the differences in sensitivity to EGFR TKIs between patients carrying exon 19 deletions and the L858 mutation in exon 21, but the conclusions have been controversial. [10] [11] [12] [13] Notably, most of these studies have been performed in relatively small cohorts with limited types and numbers of mutations in the different exons. In addition, most studies have included patients receiving variable lines of EGFR TKI treatment. More recently, studies by Kaneda et al. and Chung et al. have reported significant differences in treatment outcomes to EGFR TKI therapy in patients carrying different exon 19 deletion subtypes.
14,15 However, these studies were also limited by the small study cohorts, potential selection bias, and inclusion of patients receiving variable lines of EGFR TKI therapy. In a recent meta-analysis conducted by Sheng et al., 16 patients with exon 19 deletions had significantly longer progression-free survival (PFS) and overall survival (OS) compared with those carrying exon 21 L858R mutation. However, this meta-analysis included studies that were performed in unselected groups of patients receiving different EGFR TKI treatments. This study was therefore conducted with the primary objective of evaluating the differences in survival outcomes among patients with advanced NSCLC who were specifically receiving firstline gefitinib treatment and carrying different EGFR mutation types and subtypes.
Materials and Methods

Study Design and Patient Selection
This was a retrospective, observational cohort study involving patients with a documented diagnosis of NSCLC who received treatment in our center from October 1995 to August 2015. Of the 2111 patients with lung cancer with known EGFR mutation status, 383 patients were included for evaluation on the basis of the following inclusion criteria: having stage IIIB or IV NSCLC, carrying somatic EGFR mutations, having received gefitinib as first-line treatment, and being of Asian descent.
The demographics and clinical information of eligible patients, including age, sex, smoking history, histological subtype, clinical stage of disease at diagnosis, presence of metastasis, performance status, survival, and treatment outcomes, were retrospectively obtained from medical records and Lung Cancer Consortium Singapore. Clinical stages were assigned according to the seventh edition of the American Joint Committee on Cancer. Disease evaluation was performed according to the Response Evaluation Criteria in Solid Tumors, version 1.1. This study was approved by the institutional review board of Singapore Health Services (SingHealth CIRB 2010/516/B) and conducted in accordance with the principles expressed in the Declaration of Helsinki.
EGFR Mutation Analysis
Genomic DNA was extracted from formalin-fixed paraffin-embedded samples with the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. Target sequences in exons 18, 19, 20 , and 21 were amplified by polymerase chain reaction and the polymerase chain reaction products were then subjected to analysis for EGFR mutations by direct Sanger sequencing.
Statistical Analysis
OS and PFS were estimated by the Kaplan-Meier method. OS was defined as the time from the start of first-line TKI treatment to death. OS data for survivors were censored at the last follow-up date. PFS was defined as the time from the start of first-line TKI treatment to disease progression or death, whichever was earlier, and data were censored at the last follow-up date. The log-rank test was implemented to analyze the differences in survival between patient groups. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated by using univariate and multivariate Cox proportional hazards regression models to evaluate the effects of different variables on OS and PFS. Differences in tumor responses were compared between patient groups by using chi-square tests. Variables with a p value less than 0.05 in univariate analysis were introduced into multivariate models. A two-sided p value less than 0.05 was considered statistically significant. All analyses were performed on SPSS version 14.0 (SPSS Inc., Chicago, IL).
Results
Demographics and Clinical Characteristics
Patients' demographics and clinical characteristics are listed in 19 were further categorized into the following five subtypes according to the mutation types and number of deleted nucleotides: (1) "ELREA" 15-nucleotide deletion (delE746_A750), (2) non-ELREA 15-nucleotide deletion (delL747_T751 and delK745_ E749), (3) 18-nucleotide deletion (delL747_S752), (4) mix del/ins/sub/dup (del 15n), and (5) mix del/ins/ sub/dup (del>15n), which incorporated various exon 19 deletions as well as other insertions and substitutions (see Table 2 ). With this classification, the majority of tumors with exon 19 in-frame deletions had ELREA deletions (n ¼ 118) that accounted for 30.8% of all EGFR mutations and 53.4% of exon 19 deletions. EGFR exon 19 mutations were also categorized according to the starting codon of deletion by Gazdar et al. 17 and Lee et al. 18 When this classification was used, exon 19 deletions starting at codon E746 occurred at a higher frequency (n ¼ 138
EGFR Mutation Types and Subtypes
With regard to exon 21 mutations, the L858R mutation was the predominant subtype and was detected in 144 patients (37.6%). In contrast, the L861Q mutation was found in only six patients (1.6%). As previously reported, mutations in exons 18 and 20 were rare and occurred in eight (2.1%) and nine (2.3%) patients, respectively. The co-occurrence of double mutations was also identified in 20 patients (5.2%). (Fig. 1D) . With regard to exon 21 mutation subtypes, a trend of higher PFS was observed in patients with the L858R mutation than in those harboring the L861Q mutation, but statistical significance was not achieved (median PFS of 8 (Fig. 1E) . These findings were consistently observed in further subgroup analyses performed specifically in patients with advanced NSCLC of the adenocarcinoma histological subtype. These findings were also consistently observed with patients receiving erlotinib and afatinib included in the analysis ( Supplementary Figs. 1A-E) . 
Clinicopathological Features Associated with PFS
Univariate analysis indicated that cancer histological subtype, ECOG performance status, and EGFR mutation type were significant factors for PFS (Table 3 ). All other factors, including sex and EGFR exon 19 mutation subtypes, were not associated with PFS. Upon multivariate adjustments using the Cox proportional hazards model, all three factors remained independent predictors of PFS (see Table 3 ). Specifically, a significantly higher HR was associated with EGFR mutation in exon 21 than in exon 19 (HR ¼ 1.40, 95% CI: 1.07-1.82, p ¼ 0.014). This association remained significant in a further subgroup analysis performed in patients with the adenocarcinoma histological subtype of NSCLC who were treated with EGFR TKIs alone (data not shown). 
OS according to EGFR Mutation Types and Subtypes
The median OS in this patient cohort was 18.2 months. No significant difference was observed in OS among patients carrying EGFR mutations on different exons (overall p ¼ 0.054 [ Fig. 2A]) . In contrast to PFS, comparison of OS between patients with exon 19 mutations and specifically the L858R mutation in exon 21 showed no statistically significant difference (p ¼ 0.121 [ Fig. 2B]) .
Interestingly, OS was found to be significantly different among the various subtypes of exon 19 mutations, with the 15-nucleotide deletion non-ELREA group having the shortest OS (i.e., 11.3 months [overall p ¼ 0.025]) (Fig. 2C) . Univariate analysis revealed a trend of higher HR in patients with the 15-nucleotide non-ELREA deletion than in the group of patients carrying the 15-nucleotide ELREA deletion (HR ¼ 1.82, 95% CI: 0.96-3.44, p ¼ 0.066) ( Table 4 ). In addition, patients in the group with mix del/ins/sub (del >15 nucleotide) were observed to have a significantly lower HR compared with the reference ELREA group (HR ¼ 0.46, 95% CI: 0.25-0.86, p ¼ 0.015) (see Table 4 ).
However, no significant difference was observed in OS between patients with exon 19 deletions starting at codon E746 versus at codon L747 (p ¼ 0.737) (Fig. 2D) . With regard to exon 21 mutations, patients with L858R mutation had significantly longer OS (16.4 months) than those with L861Q mutation (8.2 months [HR ¼ 2.57, 95% CI: 1.10-5.96, p ¼ 0.028). These results remained consistent in subsequent analyses conducted in patients with advanced NSCLC of the adenocarcinoma histological subtype. These findings were also consistently observed with patients receiving erlotinib and afatinib included in the analysis (Supplementary Figs. 2A-E) .
Clinicopathological Features Associated with OS
The factors associated with OS in univariate analysis included family history of cancer, histological subtype, ECOG performance status, EGFR exon 19 mutation subtype, and exon 21 mutation subtype (see Table 4 ). Two multivariate models were subsequently tested for OS: the first model considered EGFR exon 19 mutation subtypes whereas the second model considered EGFR exon 21 mutation subtypes. Both models included the following variables: family history, histological classification, and ECOG score. In multivariate model 1, EGFR exon 19 mutation subtypes remained a significant predictor of OS, with patients in the 15-nucleotide ELREA deletion group having significantly longer OS than those in the non-ELREA deletion group (HR ¼ 2.27, 95% CI: 1.04-4.95, p ¼ 0.040) and shorter OS than those in the mix del/sub/ins (del>15n) group (HR ¼ 0.49, 95% CI: Table 4 ). In addition to EGFR exon 19 mutation subtype, ECOG performance status was also shown to be an independent predictor of OS in multivariate analysis.
In a separate multivariate model that included EGFR exon 21 mutation subtypes, ECOG performance status was found to be the only remaining significant predictor of OS (see Table 4 ). However, it is worthwhile to note that higher risk for death was associated with the L861Q mutation than with the L858R mutation in exon 21 in this multivariate model, although this finding was of marginal significance (HR ¼ 2.60, 95% CI: 0.93-7.28, p ¼ 0.068) (see Table 4 ). 
Discussion
The discovery that EGFR activating mutations confer increased sensitivity to EGFR TKIs in patients with NSCLC has led to a paradigm shift in the management of patients with advanced NSCLC harboring these mutations, and EGFR TKIs are now considered first-line treatment in this setting. 3, 9, 13 However, differential survival outcomes in response to EGFR TKIs have been observed and the causes underlying such variability remain unaccounted for. To our knowledge, the present study, in which we aimed to evaluate the influence of EGFR mutation types and subtypes on survival outcomes after first-line gefitinib therapy, represents the largest reported cohort of Asian patients with NSCLC (N ¼ 388). This study specifically included patients with advanced (stage IIIB or IV) disease who were receiving first-line gefitinib treatment, whereas many of the previous series included patients whose disease was in various stages 15, 19 and who were receiving different EGFR TKIs and for variable lines of treatment. 14, 15 Our data strongly suggest that the observed survival differences among patients with advanced NSCLC harboring EGFR mutations and receiving gefitinib therapy may be explained at least partially by the genetic heterogeneity in the types and subtypes of EGFR mutations.
Both deletions in exon 19 and L858R point mutation in exon 21 of the EGFR gene have been reported to be important predictors of improved response to EGFR TKIs. 9, 11 However, in a comparison of these two most prevalent EGFR mutations, our Asian patients with NSCLC with EGFR exon 19 deletion mutations had a median PFS that was approximately 2 months longer than that of those with the EGFR L858R point mutation (p ¼ 0.005), and this difference remained significant in multivariate analysis, although no significant differences were observed in terms of OS. Indeed, in vitro kinetic assays have demonstrated higher affinity of EGFR TKIs for recombinant EGFR with exon 19 deletion than exon 21 L858R mutation. 20 In addition, differences in patterns of EGFR phosphorylation and constitutive downstream activation pathways in NSCLC cell lines carrying exon 19 mutation and L858R exon 21 mutation have been reported. 21, 22 These findings are also in general agreement with previous reports by Jackman et al., 12 Riely et al., 11 and Sun et al., 23 which reported longer PFS and/or OS in patients harboring EGFR exon 19 deletions than in those with L858R mutation in exon 21. In contrast to these findings, however, several other studies have reported no significant differences in PFS and OS between these two subgroups of patients. [24] [25] [26] These contradictory findings may be due in part to the limited sample sizes in previous studies and to the fact that different subsets of patients who had different clinicopathological characteristics and were receiving different EGFR TKIs were included for analysis.
Importantly, exon 19 mutations comprise a heterogeneous group of genetic aberrations, including various in-frame deletions, substitutions and insertions. Specifically, those in the 15-nucleotide non-ELREA deletion group were found to have significantly shorter median OS than those in the 15-nucleotide ELREA deletion group despite both being 15-nucleotide-long deletions, which has never been previously reported. Recently, Lee et al. also reported significant differences in PFS among patients with NSCLC carrying different exon 19 mutation subtypes, but the investigators did not subcategorize those with different 15-nucleotide deletions, which renders direct comparison with our findings impossible. 18 In addition, Kaneda et al., 14 Gazdar et al., 17 and Lee et al. 18 also categorized exon 19 deletions according to the start codon of the deletion and found significant differences in survival outcomes between patients with exon 19 deletions starting on codon E746 versus on codon L747. In contrast to these findings, we did not find significant differences in OS and PFS between these two subgroups. However, our findings regarding the influence of exon 21 mutation subtypes on survival after EGFR TKIs in patients with advanced NSCLC concurred with those of Lee et al., 18 with patients harboring the L858R mutation having significantly longer OS and a trend of longer PFS compared with that of those harboring the L861Q mutation.
We recognize the limitations of this retrospective analysis. The standard interval of radiological imaging for EGFR-mutant lung cancers responding to TKIs in our center ranges from 8 to 12 weeks. Length of time bias caused by varying intervals of radiological imaging could lead to differences observed in PFS, but it does not affect OS. Notably, the proportion of patients who received treatment after gefitinib therapy was comparable between patients with exon 19 or exon 21 mutations and would not likely influence the differences observed in OS (Supplementary Table 1 ). In addition, the molecular and structural mechanisms underlying these differences in sensitivity to EGFR TKIs between the different types and subtypes of EGFR mutations have not been explored and reported, which would be crucial in advancing our current understanding of the influence of specific aberrations in the EGFR gene on response and survival outcomes in response to EGFR TKI treatment. Nevertheless, these findings warrant confirmation in a future prospective study and suggest the need for future therapeutic trials to consider EGFR mutation types and subtypes as stratification factors.
